[4-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-phenylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [4-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-phenylamine
• 英文别名: 4-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-N-phenylpyrimidin-2-amine；4-(3-methyl-1-phenylpyrazol-4-yl)-N-phenylpyrimidin-2-amine
• 化学式: C₂₀H₁₇N₅
• 分子量: 327.388
• InChiKey: BUXGLXHIUZIERX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-methanesulfonyl-4-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-pyrimidine 在 氮 、 甲醇 作用下， 以 苯胺 为溶剂， 反应 15.0h， 以provided the product (23 mg, 0.070 mmol) in 58% yield的产率得到[4-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-phenylamine
  参考文献：
  名称：

  Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases

  摘要：

  本发明提供了I式化合物，其中G是氢或C1-3烷基，Q是吡啶或嘧啶，R1-R3如规范所定义。这些化合物是选择性JNK抑制剂，对JNK的三种亚型（JNK1、JNK2和JNK3）具有良好的活性，而对p38激酶的活性相对较低。因此，这些化合物对于治疗JNK介导的疾病，特别是所有三种JNK亚型都涉及的神经退行性疾病是有用的。

  公开号：

  US20020111353A1

文献信息

• INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1343781B1

  公开（公告）日：2008-09-03
• Therapeutic Methods For Type I Diabetes
  申请人：Davis Roger J.

  公开号：US20120208846A1

  公开（公告）日：2012-08-16

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.
• Therapeutic Methods for Type I Diabetes
  申请人：UNIVERSITY OF MASSACHUSETTS

  公开号：US20150313881A1

  公开（公告）日：2015-11-05

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.
• US7897572B1
  申请人：——

  公开号：US7897572B1

  公开（公告）日：2011-03-01
• US8501812B2
  申请人：——

  公开号：US8501812B2

  公开（公告）日：2013-08-06